Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500 million of proceeds to Insulet, before deducting underwriting discounts and estimated offering expenses. Insulet’s common stock is listed on the Nasdaq Global Select Market under the symbol “PODD.”

Insulet, headquartered in Massachusetts, is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod System, an innovative, continuous insulin delivery system for people with insulin-dependent diabetes.

The Davis Polk capital markets team included partner Yasin Keshvargar and associates Andrew J. Terjesen, Blake Anderson and Paula Gergen. The tax team included partner Po Sit and associate Tomislava Dragicevic. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Members of the Davis Polk team are based in the New York and Northern California offices.

 

Copy link to share post